上述专利为公司自主研发，其所涉及技术均与公司主营业务产品技术相关， 专利权自授权公告之日起生效。 上述专利的取得和运用，不会对公司短期的经营业绩构成重大影响，但有利 于公司进一步完善知识产权保护体系，形成持续创新机制，保持技术的领先地位， 提升公司的核心竞争力。 特此公告。 证券代码：301122 证券简称：采纳股份 公告编号：2024-076 采纳科技股份有限公司 关于公司取得专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"或"采纳股份"）于近日收到国 家知识产权局颁发的专利证书，具体情况如下： | 序号 | 专利名称 | 专利类型 | 专利号 | 专利权人 | | 授权公告日 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 动物用注射器 | 发明专利 | ZL | 采纳股份 | 2024 | 年 | 09 | | | | | 201811530323.6 | | 月 | 10 | 日 | | 2 | 电动或气动连续注 | 发明专利 ...

采纳科技股份有限公司 关于参股公司获准挂牌新三板的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：301122 证券简称：采纳股份 公告编号：2024-075 二、振宏股份挂牌的影响 采纳科技股份有限公司（以下简称"公司"）参股公司振宏重工（江苏）股 份有限公司（以下简称"振宏股份"）近日收到全国中小企业股份转让系统有限 责任公司出具的《关于同意振宏重工（江苏）股份有限公司股票公开转让并在全 国股转系统挂牌的函》（股转函[2024]2547 号），同意振宏股份股票公开转让并 在全国中小企业股份转让系统（以下简称"新三板"）挂牌，交易方式为集合竞 价。振宏股份将按照相关规定办理挂牌手续。 一、振宏股份的基本情况 1、公司名称：振宏重工（江苏）股份有限公司 2、注册资本：7865 万元人民币 3、法定代表人：赵正洪 4、成立日期：2005-01-26 5、注册地址：江阴市芙蓉大道东段 888 号 6、统一社会信用代码：913202817698615719 7、经营范围：许可项目：道路货物运输（不含危险货物）（依法须经批准 的项目，经相关部门批准后方 ...

证券代码：301122 证券简称：采纳股份 公告编号：2024-074 采纳科技股份有限公司 关于使用部分闲置募集资金和自有资金 进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）召开的第三届董事会第五次会 议、第三届监事会第五次会议、2024 年第一次临时股东大会，分别审议通过了 《关于使用部分闲置募集资金和自有资金进行现金管理的议案》，同意公司及全 资子公司在确保不影响募集资金投资项目和公司正常经营，并有效控制风险的前 提下，使用额度不超过人民币 50,000 万元（含本数）的闲置募集资金（含超募 资金）和额度不超过人民币 80,000 万元（含本数）的自有资金进行现金管理。 使用期限自股东大会审议通过之日起 12 个月内有效。在上述额度和期限内，资 金可循环滚动使用。 同时，在额度范围内授权公司管理层行使相关投资决策权并签署相关文件， 具体由公司财务部负责组织实施。 具体内容详见公司在巨潮资讯网 （www.cninfo.com.cn）披露的相关公告。 注：公司与上述受托方无关联关系。 二、投资 ...

证券代码：301122 证券简称：采纳股份 公告编号：2024-073 采纳科技股份有限公司 采纳科技股份有限公司（以下简称"公司"）于 2024 年 5 月 10 日召开了第 三届董事会第八次会议，审议通过了《关于拟设立境外控股子公司的议案》。具 体内容详见公司披露于巨潮资讯网（http://www.cninfo.com.cn）的《关于对外 投资设立境外控股子公司的公告》（公告编号 2024-036）。 二、对外投资进展情况 公司于近日收到柬埔寨商业部颁发《公司注册证》具体情况如下： 关于对外投资的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、对外投资概述 1、公司名称：CAMEDICAL TECHNOLOGY (CAMBODIA) CO., LTD.（凯美医疗科 技（柬埔寨）有限公司，以下简称"CAMEDICAL TECHNOLOGY"） 2、注册编号：1000418888 3、注册资本：20,000,000,000（柬埔寨瑞尔）（折合人民币约为：3,495 万 元人民币 4、公司类型：Private Limited Company （私人 ...

Financial Performance - In the first half of 2024, the company achieved operating revenue of 194.43 million CNY, a year-on-year increase of 9.78% [2] - The net profit attributable to shareholders was 33.20 million CNY, a year-on-year decrease of 35.30% [2] - The comprehensive gross profit margin for the period was 39.18%, indicating stable profitability [3] Business Segments - The medical device segment accounted for 54.87% of total revenue, generating 106.68 million CNY [2] - The animal device segment contributed 37.51% to total revenue, with earnings of 72.93 million CNY [2] - The laboratory consumables segment represented 6.09% of total revenue, totaling 11.85 million CNY [2] Market and Orders - The company reported a signed contract revenue amount of 106.13 million CNY, excluding products affected by the FDA import warning [3] - The company plans to actively expand into the European market and gradually establish domestic channels [3] Regulatory and Compliance - The company received the EU MDR certification for approximately 40 products in July 2024, enhancing its market access in Europe [4] - The FDA issued an import warning in April 2024 affecting certain products, which the company is addressing through legal channels [3] Future Development Plans - The company aims to strengthen its core technologies in the medical health sector and expand its product lines [5] - Plans include establishing a joint venture in Singapore and a project company in Cambodia to enhance production capabilities [3] - The company will focus on increasing R&D investment and improving product competitiveness to capture domestic market opportunities [4]

证券代码：301122 证券简称：采纳股份 公告编号：2024-072 1、公司拟购买的投资产品属短期低风险型产品，但金融市场受宏观经济影 响较大，该项投资会受到市场波动的影响； 1 / 7 采纳科技股份有限公司 关于使用部分闲置募集资金和自有资金 进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）召开的第三届董事会第五次会 议、第三届监事会第五次会议、2024 年第一次临时股东大会，分别审议通过了 《关于使用部分闲置募集资金和自有资金进行现金管理的议案》，同意公司及全 资子公司在确保不影响募集资金投资项目和公司正常经营，并有效控制风险的前 提下，使用额度不超过人民币 50,000 万元（含本数）的闲置募集资金（含超募 资金）和额度不超过人民币 80,000 万元（含本数）的自有资金进行现金管理。 使用期限自股东大会审议通过之日起 12 个月内有效。在上述额度和期限内，资 金可循环滚动使用。 同时，在额度范围内授权公司管理层行使相关投资决策权并签署相关文件， 具体由公司财务部负责组织实施。 具体内容 ...

采纳科技股份有限公司 关于向金融机构申请综合授信额度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）于 2024 年 8 月 26 日召开了第 三届董事会第十次会议，审议通过了《关于公司向金融机构申请综合授信额度的 议案》，现将相关情况公告如下： 为满足公司及其下属全资子公司的生产经营的需求，并考虑到资金的合理配 置和利用，公司拟向金融机构申请授信额度不超过 15,000 万元的综合授信。 证券代码：301122 证券简称：采纳股份 公告编号：2024-070 综合授信内容包括但不限于流动资金贷款、各类商业票据开立及贴现、项目 贷款、银行保函、保理、银行承兑汇票、开立信用证等综合授信业务（具体业务 品种以相关金融机构审批为准）。各金融机构具体授信额度、贷款利率、费用标 准、授信期限等以公司与金融机构最终协商签订的授信申请协议为准。上述综合 授信额度的申请期限为董事会审议通过之日起 12 个月止，该授信额度可用于公 司及其下属全资子公司，在申请期限内可循环使用。 公司拟授权董事长办理授信及提供质押增信措施等所有授信 ...

Financial Performance - The company's operating revenue for the first half of 2024 was CNY 194,427,862.11, representing a 9.78% increase compared to CNY 177,103,036.34 in the same period last year[12]. - The net profit attributable to shareholders for the first half of 2024 was CNY 33,198,850.27, a decrease of 35.30% from CNY 51,312,384.41 in the previous year[12]. - The basic earnings per share for the first half of 2024 was CNY 0.27, down 35.71% from CNY 0.42 in the same period last year[12]. - The total operating costs for the first half of 2024 were ¥147,912,236.71, up from ¥134,107,063.79 in the first half of 2023, reflecting a year-over-year increase of 10.5%[129]. - The operating profit for the first half of 2024 was ¥37,232,274.46, down from ¥59,022,312.41 in the first half of 2023, representing a decrease of 37.0%[129]. - The company’s total profit for the first half of 2024 was ¥37,216,240.48, compared to ¥59,048,554.92 in the first half of 2023, reflecting a decline of 37.0%[130]. - The financial expenses for the first half of 2024 showed a net income of -¥5,027,780.21, an improvement from -¥6,101,471.82 in the first half of 2023[129]. - The company reported a significant decrease in investment income, which fell to ¥7,645,299.00 in the first half of 2024 from ¥12,039,768.41 in the same period of 2023, a decline of 36.5%[129]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,899,571,663.17, reflecting a decrease of 1.53% from CNY 1,929,096,040.45 at the end of the previous year[12]. - The net assets attributable to shareholders at the end of the reporting period were CNY 1,790,892,165.14, a decrease of 0.87% from CNY 1,806,591,578.07 at the end of the previous year[12]. - The company's total assets included cash and cash equivalents amounting to ¥314,578,817.99, which is 16.56% of total assets, up from 9.24% the previous year[55]. - Total liabilities decreased from CNY 122,504,462.38 to CNY 108,679,498.03, a decline of about 11.3%[124]. - Owner's equity decreased from CNY 1,806,591,578.07 to CNY 1,790,892,165.14, a reduction of approximately 0.9%[124]. Cash Flow - The net cash flow from operating activities for the first half of 2024 was CNY 21,451,268.80, a decrease of 43.24% compared to CNY 37,791,429.31 in the same period last year[12]. - Cash inflow from operating activities reached CNY 229,454,401.56, an increase from CNY 211,960,964.40 year-over-year[133]. - Net cash flow from operating activities was CNY 54,951,807.61, up from CNY 51,261,257.56 in the previous year[133]. - Cash inflow from investment activities totaled CNY 1,054,041,241.59, compared to CNY 801,218,718.41 in the first half of 2023[134]. - The company reported a net cash increase of CNY 136,249,534.80, contrasting with a decrease of CNY 16,137,045.84 in the previous year[134]. Research and Development - Research and development expenses increased by 28.43% to ¥12,513,397.91 from ¥9,743,330.98 in the previous year[50]. - The company focuses on independent research and development of laboratory consumables to meet customer and market demands[36]. - The company has established a research and development system focused on market needs, with dedicated research centers for veterinary puncture instruments and safety self-destruct syringes[39]. - The company aims to enhance its R&D capabilities to maintain a competitive edge in the injection and puncture device industry, particularly in high-end, intelligent, and safe products[77]. Market Position and Strategy - The company is a leading manufacturer of medical devices, with a diverse product line including safety injection needles, sterile syringes, and insulin syringes[23][24]. - The company holds the number one market share in the domestic animal injection needle market, according to FROST & SULLIVAN, with a strong focus on core technology and market competitiveness[35]. - The company aims to enhance its market position in high safety and high value-added products while expanding into new channels and emerging markets[34]. - The company is positioned to benefit from the growing demand in the pet healthcare market and the increasing standardization in livestock management practices in China[38]. Compliance and Quality Management - The company has achieved multiple international quality certifications, including ISO9001 and ISO13485, ensuring compliance with global standards[16]. - The company emphasizes strict quality management and control measures to ensure compliance with international standards, including ISO13485 and FDA regulations[81]. - The company has implemented a comprehensive quality management system, achieving ISO13485 and MDSAP certifications, and its products have received CE certification and FDA registration[41]. - The company’s quality control measures cover all stages from design to disposal, ensuring compliance with regulatory requirements[41]. Risks and Challenges - The company is facing various risks, which are detailed in the report, and investors are advised to read this section carefully[2]. - The company is facing an import warning from the FDA, which may significantly impact future main business income and profits[82]. - The company has made provisions for inventory impairment due to the FDA warning, anticipating a major impact on future business income and profits[107]. - The company is actively monitoring exchange rate fluctuations and utilizing financial tools to manage foreign exchange risks[78]. Corporate Governance - The company has established a multi-tier governance structure, including a board of directors and various specialized committees[149]. - The company operates under the legal framework and regulations of the country, ensuring compliance in its operations[149]. - The company has maintained open communication channels with investors, ensuring timely responses to inquiries[87]. Shareholder Information - The total number of shares is 122,245,658, with 63.81% being restricted shares[110]. - The profit distribution plan for 2023 was approved, with a cash dividend of CNY 4.00 per 10 shares, totaling CNY 48,898,263.20, implemented in May 2024[108]. - The largest shareholder, Lu Jun, holds 28.29% of shares (34,580,000 shares) [112]. - The total equity attributable to shareholders at the end of the reporting period is RMB 1,501,437,235.54[147].

采纳科技股份有限公司 2024 年半年度非经营性资金占用及其他关联资金往来情况汇总表 法定代表人：陆军 主管会计工作负责人： 查凌云 会计机构负责人：查凌云 编制单位：采纳科技股份有限公司 单位：万元 | | | 占用方与上 | 上市公司核算的 | 2024 年期初占 | 2024 年半年度占 | 2024 年半年度 | 2024 年半年度 | 2024 年 6 月末 | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 市公司的关 | 会计科目 | 用资金余额 | 用累计发生金额 | 占用资金的利 | 偿还累计发生 | 占用资金余额 | 原因 | 占用性质 | | | | 联关系 | | | （不含利息） | 息（如有） | 金额 | | | | | 控股股东、实际控制人及 | - | - | - | - | - | - | - | - | - | 非经营性 | | 其附属企业 | - | - | - | - | - | - | - | - | - | 非经营 ...

海通证券股份有限公司关于采纳科技股份有限公司 2024 年半年度跟踪报告 | 保荐机构名称：海通证券股份有限公司 | 被保荐公司简称：采纳股份 | | --- | --- | | 保荐代表人姓名：钟祝可 | 联系电话：021-23180000 | | 保荐代表人姓名：张刚 | 联系电话：021-23180000 | 一、保荐工作概述 | 项 目 | 工作内容 | | --- | --- | | 1、公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 不适用 | | 2、督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限 于防止关联方占用公司资源的制度、募集资金管理 | 是 | | 制度、内控制度、内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3、募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 1 | | （2）公司募集资金项目进展是否与信息披露文件一 | | | 致 | 是 | | 4、公司治理督导情况 | | | （ ...